icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
 
 
 
EASL 2019 HCV Highlights Report: Treatment, Retreatment, Elimination, Fatty Liver/HIV, Resistance Testing, Reinfection
 
 
  HCV at EASL 2019: Treatment, Elimination; Fatty Liver & HIV / HCV Resistance Testing / Reinfection / HCV Treatment: Sofosbuvir/Velpatasvr, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir - Sofosbuvir+Glecaprevir/Pibrentasvir
 
The International Liver Congress™
EASL - European Association for the
Study of the Liver

2019 April 10-14
Vienna Austria
 
Fatty Liver, NASH, NAFLD
 
Selected Highlights
 

0509191

EASL: Best of ILC 2019 Viral hepatitis - (04/18/19)
 
EASL: REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY - (04/13/19)
 
EASL: Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir - (04/12/19)
 
HCV EASL Treatment Guidelines / 16-24 Weeks Retreatment / Retreatment of patients who failed after a protease inhibitor- and/or NS5A inhibitor-containing regimen - (04/30/19)
 
EASL: Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C: Integrated analysis of 12 clinical practice cohorts - (04/12/19)
 
EASL: High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis - (04/13/19)
 
EASL: Real-World Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in HCV: A Multi -Country Analysis of Post-Marketing Observational Studies - (04/12/19)
 
EASL: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (04/15/19)
 
EASL: Prospective Multicenter Study of Glecaprevir + Pibrentasvir Combination Therapy for Patients with Chronic Hepatitis C - (04/22/19)
 
EASL: Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV-infected patients with chronic kidney disease - (04/22/19)
 
EASL: Clinical practice experience with pangenotypic therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir; data from the TRIO Network - (04/12/19)
 
EASL: Effectiveness of the salvage therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C; clinical practice experience from the TRIO network - (04/12/19)
 
EASL: Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure - an analysis from the German Hepatitis C-Registry (DHC-R) - (04/12/19)
 
EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Na´ve Patients With Chronic Hepatitis C Virus Infection Without Cirrhosis or With Compensated Cirrhosis: Analysis of Data Pooled From Phase 2 and 3 Studies - (04/13/19)
 
Barrier To Access/Treatment - EASL: Patient Flow Across Physician Specialties Over the Course of the Hepatitis C Care Cascade: A Real-World Analysis From the United States - (04/13/19)
 
EASL: EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR FOR RETREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH A PREVIOUS FAILURE TO DIRECT-ACTING ANTIVIRALS: A REAL-LIFE STUDY FROM THE NAVIGATORE LOMBARDIA AND VENETO NETWORKS - (04/13/19)
 
EASL: Efficacy and safety of Glecaprevir/Pibrentasvir in patients with severe renal impairment in Japan: a prospective, multicenter study (KTK 49 Liver Study Group) - (04/22/19)
 
EASL: - Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV-infected patients with chronic kidney disease (04/22/19)
 
EASL: Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: An Integrated Analysis of Phase 2 and 3 Studies - (04/13/19)
 
EASL: Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir - (04/12/19)
 
EASL: Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment - (04/13/19)
 
EASL: Sofosbuvir + Velpatasvir + Voxilaprevir in DAA Failure Patients with Cirrhosis Final Results of the French Compassionate Use Program - (04/13/19)
 
EASL: Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy - (04/13/19)
 
EASL: Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: Implications for global elimination - (04/18/19)
 
EASL: Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvirfor six weeks among people with acute and recent HCV infection - (04/22/19)
 
EASL: 4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC) - (04/22/19)
 
EASL: EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION WHO RECEIVE OPIOID AGONIST THERAPY: TREATMENT UTILIZATION AND THE IMPACT OF CONCOMITANT PSYCHIATRIC MEDICATIONS - (04/17/19)
 
EASL: Real world effectiveness and utilization patterns of Elbasvir/Grazoprevir for treatment of HCV G1 G4 infected patients in Italy - (04/17/19)
 
EASL: HIGH REAL-WORLD EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN PWID ON OPIOID SUBSTITUTION THERAPY WITH HCV GENOTYPE 1 (GT1) INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)
 
EASL: HIGH EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS WITH HCV GENOTYPE 1A (GT1A) INFECTION IN GERMAN REAL-WORLD: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)
 
EASL: Effectiveness of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Genotype 1 Infection Receiving Dialysis - (04/15/19)
 
EASL: PRO: Testing for HCV Resistance-Associated Variants (RAVs) in Patients After DAA Failure and Impact on Subsequent Drug Selection - (04/26/19)
 
EASL: CONTRA Testing for HCV RASs after DAA Failure and Choices of Retreatment - (04/30/19)
 

0509192

EASL: - HCV Elimination Off-Track WHO Targets/Countries Estimates - Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets (04/15/19)
 
EASL: Achieving accelerated elimination of hepatitis C virus infection by 2025: a case study in France - (04/15/19)
 
EASL: Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study - (04/18/19)
 
EASL: New in France: Universal Access for HCV-treatment as demonstrated by a nationwide real-world cohort - (05/07/19)
 
EASL: Rwanda HCV Elimination Project - (05/07/19)
 
EASL: The global investment case for hepatitis C elimination - (04/17/19)
 

0509193

EASL: HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY - (04/17/19)
 
EASL: Reinfection following successful HCV DAA therapy among people with recent injecting drug use - (04/15/19)
 

0509194

EASL: APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)
 
EASL: The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)
 
EASL: HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)
 
EASL: The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)
 
EASL: The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)
 
EASL: Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)
 
EASL: Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)
 
EASL: EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)
 
EASL: Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)
 
EASL: Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)
 
EASL: LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)
 
EASL: Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)
 
The Interplay Between Nonalcoholic Fatty Liver Disease and Atherosclerotic Heart Disease - Editorial - (04/10/19)
 
AbbVie wins hep C contract with Washington state in latest 'Netflix' deal - (04/30/19)
 
Health Care Authority announces AbbVie US LLC as apparently successful bidder for hepatitis C virus treatment drug - (04/30/19)
 
New Global Hepatitis Funding - HCV-HBV-NASH-HCV/HIV Coinfection Screening, Care , Linkage to Care - (04/09/19)